GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (FRA:7RG0) » Definitions » Cyclically Adjusted Book per Share

Regulus Therapeutics (FRA:7RG0) Cyclically Adjusted Book per Share : €95.60 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Regulus Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Regulus Therapeutics's adjusted book value per share for the three months ended in Jun. 2024 was €1.393. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €95.60 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Regulus Therapeutics's average Cyclically Adjusted Book Growth Rate was -24.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-11-13), Regulus Therapeutics's current stock price is €1.30. Regulus Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €95.60. Regulus Therapeutics's Cyclically Adjusted PB Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regulus Therapeutics was 0.03. The lowest was 0.00. And the median was 0.00.


Regulus Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Regulus Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Cyclically Adjusted Book per Share Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -581.15 99.80 118.90 92.38

Regulus Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.57 106.39 92.38 89.47 95.60

Competitive Comparison of Regulus Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Regulus Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Cyclically Adjusted PB Ratio falls into.



Regulus Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regulus Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book= Book Value per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.393/132.5538*132.5538
=1.393

Current CPI (Jun. 2024) = 132.5538.

Regulus Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201409 158.805 100.428 209.605
201412 262.493 99.070 351.212
201503 320.708 99.621 426.728
201506 275.175 100.684 362.277
201509 257.097 100.392 339.463
201512 259.516 99.792 344.714
201603 218.950 100.470 288.868
201606 179.347 101.688 233.785
201609 146.846 101.861 191.094
201612 120.531 101.863 156.847
201703 81.707 102.862 105.292
201706 40.155 103.349 51.502
201709 47.051 104.136 59.891
201712 34.351 104.011 43.778
201803 21.341 105.290 26.867
201806 10.263 106.317 12.796
201809 1.545 106.507 1.923
201812 -5.836 105.998 -7.298
201903 -4.965 107.251 -6.136
201906 2.016 108.070 2.473
201909 -0.062 108.329 -0.076
201912 8.569 108.420 10.476
202003 4.884 108.902 5.945
202006 2.121 108.767 2.585
202009 1.680 109.815 2.028
202012 3.172 109.897 3.826
202103 3.049 111.754 3.616
202106 3.512 114.631 4.061
202109 2.833 115.734 3.245
202112 3.332 117.630 3.755
202203 3.062 121.301 3.346
202206 2.738 125.017 2.903
202209 2.379 125.227 2.518
202212 1.866 125.222 1.975
202303 1.473 127.348 1.533
202306 1.610 128.729 1.658
202309 1.309 129.860 1.336
202312 0.960 129.419 0.983
202403 1.512 131.776 1.521
202406 1.393 132.554 1.393

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Regulus Therapeutics  (FRA:7RG0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regulus Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.30/95.6
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regulus Therapeutics was 0.03. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Regulus Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Regulus Therapeutics Headlines

No Headlines